{
  "id": "resp_0250d6e80fe0e19e00693c90012f108196be18a39b94773c00",
  "object": "response",
  "created_at": 1765576705,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_0250d6e80fe0e19e00693c9001bb008196bd2efbcdd6c1be43",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0250d6e80fe0e19e00693c900615fc8196b0db3a455161eafd",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"CDK12/13 inhibitor\" site:clinicaltrials.gov \"phase 1\""
      }
    },
    {
      "id": "rs_0250d6e80fe0e19e00693c900808fc81969d59b733c20af5da",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0250d6e80fe0e19e00693c900857148196931c318bca22ab97",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"CDK12/13 inhibitor\" site:clinicaltrials.gov phase 1"
      }
    },
    {
      "id": "rs_0250d6e80fe0e19e00693c900a1b008196bf534afcb8f360cb",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0250d6e80fe0e19e00693c900dee4481969f7663381a7a5e6e",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrials.gov CDK12/13 inhibitor NCT"
      }
    },
    {
      "id": "rs_0250d6e80fe0e19e00693c90104098819695a5f2559c807b8d",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0250d6e80fe0e19e00693c9012d4ac8196b79a880390ca0d4c",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"CDK12/13\" site:clinicaltrials.gov/study"
      }
    },
    {
      "id": "rs_0250d6e80fe0e19e00693c9014fa2c8196a02916451bd13782",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0250d6e80fe0e19e00693c9019bb108196aa55ad53fef86675",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "CDK12/13 inhibitor site:clinicaltrials.gov/study Phase 1"
      }
    },
    {
      "id": "rs_0250d6e80fe0e19e00693c901bd3c4819698f3f1f84e7fc4cd",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0250d6e80fe0e19e00693c901df7208196badfa741c7de9771",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "CT7116 site:clinicaltrials.gov"
      }
    },
    {
      "id": "rs_0250d6e80fe0e19e00693c901f9e88819685c962adc9a9f3e2",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0250d6e80fe0e19e00693c9023818c8196ad93eece9b926064",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrials.gov/study CDK12 inhibitor"
      }
    },
    {
      "id": "rs_0250d6e80fe0e19e00693c90260cc08196a6f7b861d1cb773d",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0250d6e80fe0e19e00693c9028c0188196a09a057ca6474ad6",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"cyclin-dependent kinase 12\" inhibitor site:clinicaltrials.gov \"Phase 1\""
      }
    },
    {
      "id": "rs_0250d6e80fe0e19e00693c902aa0748196ae944efbb8e516c7",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0250d6e80fe0e19e00693c902c2c6c8196ba55153401937e27",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "CDK12/13 inhibitor Phase 1 NCT"
      }
    },
    {
      "id": "rs_0250d6e80fe0e19e00693c902e8bac8196b65a11c99f6dc346",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0250d6e80fe0e19e00693c902fedd88196b465975ec9a98e33",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "NCT06600789 site:clinicaltrials.gov"
      }
    },
    {
      "id": "rs_0250d6e80fe0e19e00693c9031e9988196b8347a454053bd33",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0250d6e80fe0e19e00693c9032c3208196a571d734b9bc50f7",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://clinicaltrials.gov/study/NCT06600789"
      }
    },
    {
      "id": "rs_0250d6e80fe0e19e00693c90339e148196b97cf8d22c215ee5",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0250d6e80fe0e19e00693c903786c08196ab047059570e9d7c",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page"
      }
    },
    {
      "id": "rs_0250d6e80fe0e19e00693c903870908196b5fd6a8e59ca3606",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0250d6e80fe0e19e00693c90395bac819695d399846bcba323",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "clinicaltrials.gov/study/NCT06600789"
      }
    },
    {
      "id": "rs_0250d6e80fe0e19e00693c903c055c81968d8eed0536a66bb2",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0250d6e80fe0e19e00693c9044ccdc81968522b6e29d19f4a4",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrials.gov NCT06600789"
      }
    },
    {
      "id": "rs_0250d6e80fe0e19e00693c904882fc8196bea9a4c25199e2cd",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0250d6e80fe0e19e00693c904e5da08196bb9bca990a145488",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "clinicaltrials.gov api v2 studies NCT06600789"
      }
    },
    {
      "id": "rs_0250d6e80fe0e19e00693c9051db308196aaece1f4f271701c",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0250d6e80fe0e19e00693c9052fef88196a27acec43fa3f332",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "https://clinicaltrials.gov/api/v2/studies/NCT06600789"
      }
    },
    {
      "id": "rs_0250d6e80fe0e19e00693c9056ec0c819691b81f4c089bd389",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0250d6e80fe0e19e00693c905865bc8196a2f8b90df8c92fa7",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrials.gov \"api/v2/studies/NCT06600789\""
      }
    },
    {
      "id": "rs_0250d6e80fe0e19e00693c905a88d48196bd33a63c56fe26df",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0250d6e80fe0e19e00693c9063090c8196a8efa922f4915096",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase"
      }
    },
    {
      "id": "rs_0250d6e80fe0e19e00693c906655d88196b887661bba7edac1",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0250d6e80fe0e19e00693c9066eab481969bab6b9981852a1e",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://fdaaa.trialstracker.net/trial/NCT06600789/"
      }
    },
    {
      "id": "rs_0250d6e80fe0e19e00693c9068b3608196a1f1e3ee16a5710e",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_0250d6e80fe0e19e00693c9071a62c8196bd1a8794c1c8a1cb",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [
            {
              "type": "url_citation",
              "end_index": 469,
              "start_index": 298,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) :: Carrick Therapeutics, Inc.",
              "url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase"
            },
            {
              "type": "url_citation",
              "end_index": 815,
              "start_index": 644,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) :: Carrick Therapeutics, Inc.",
              "url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase"
            },
            {
              "type": "url_citation",
              "end_index": 1095,
              "start_index": 924,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) :: Carrick Therapeutics, Inc.",
              "url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase"
            },
            {
              "type": "url_citation",
              "end_index": 1407,
              "start_index": 1236,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) :: Carrick Therapeutics, Inc.",
              "url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase"
            },
            {
              "type": "url_citation",
              "end_index": 1627,
              "start_index": 1546,
              "title": "\n\n    \n        Trial | NCT06600789\n    \n\n",
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/"
            },
            {
              "type": "url_citation",
              "end_index": 1768,
              "start_index": 1687,
              "title": "\n\n    \n        Trial | NCT06600789\n    \n\n",
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/"
            },
            {
              "type": "url_citation",
              "end_index": 1897,
              "start_index": 1816,
              "title": "\n\n    \n        Trial | NCT06600789\n    \n\n",
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/"
            },
            {
              "type": "url_citation",
              "end_index": 2073,
              "start_index": 1992,
              "title": "\n\n    \n        Trial | NCT06600789\n    \n\n",
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/"
            },
            {
              "type": "url_citation",
              "end_index": 2306,
              "start_index": 2227,
              "title": "NCT06600789: An ongoing trial by Carrick Therapeutics Limited",
              "url": "https://fdaaa.trialstracker.net/trial/NCT06600789/"
            },
            {
              "type": "url_citation",
              "end_index": 2487,
              "start_index": 2408,
              "title": "NCT06600789: An ongoing trial by Carrick Therapeutics Limited",
              "url": "https://fdaaa.trialstracker.net/trial/NCT06600789/"
            },
            {
              "type": "url_citation",
              "end_index": 2691,
              "start_index": 2612,
              "title": "NCT06600789: An ongoing trial by Carrick Therapeutics Limited",
              "url": "https://fdaaa.trialstracker.net/trial/NCT06600789/"
            },
            {
              "type": "url_citation",
              "end_index": 2942,
              "start_index": 2862,
              "title": "CareAcross",
              "url": "https://www.careacross.com/clinical-trials/trial/NCT06600789"
            },
            {
              "type": "url_citation",
              "end_index": 3083,
              "start_index": 3003,
              "title": "CareAcross",
              "url": "https://www.careacross.com/clinical-trials/trial/NCT06600789"
            },
            {
              "type": "url_citation",
              "end_index": 3206,
              "start_index": 3126,
              "title": "CareAcross",
              "url": "https://www.careacross.com/clinical-trials/trial/NCT06600789"
            },
            {
              "type": "url_citation",
              "end_index": 3354,
              "start_index": 3274,
              "title": "CareAcross",
              "url": "https://www.careacross.com/clinical-trials/trial/NCT06600789"
            }
          ],
          "logprobs": [],
          "text": "- **Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) :: Carrick Therapeutics, Inc.**\n  - URL: `https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase` ([carricktherapeutics.com](https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase))\n  - Direct quote snippets:\n    - “Phase 1 clinical trial evaluating **CT7439**, a novel cyclin dependent kinase 12/13 (**CDK12/13**) inhibitor / **Cyclin-K glue-degrader**.” ([carricktherapeutics.com](https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase))\n    - “Clinical trial details can also be found on www.clinicaltrials.gov under study ID: **NCT06600789**.” ([carricktherapeutics.com](https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase))\n    - “The clinical trial is enrolling patients with **advanced solid tumors**, including **ovarian**, **breast** and **Ewing's Sarcoma**.” ([carricktherapeutics.com](https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase))\n\n- **Trial | NCT06600789 — Clinical Drug Experience Knowledgebase (CDEK)**\n  - URL: `https://cdek.pharmacy.purdue.edu/trial/NCT06600789/` ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT06600789/))\n  - Direct quote snippets:\n    - “Trial | **NCT06600789**” ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT06600789/))\n    - “**CT7439 Capsules (0.5 mg, 1mg, 3mg)**” ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT06600789/))\n    - “A Modular Phase 1/2 Study With **CT7439** in Participants With **Solid Malignancies**” ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT06600789/))\n\n- **NCT06600789: An ongoing trial by Carrick Therapeutics Limited — FDAAA TrialsTracker**\n  - URL: `https://fdaaa.trialstracker.net/trial/NCT06600789/` ([fdaaa.trialstracker.net](https://fdaaa.trialstracker.net/trial/NCT06600789/))\n  - Direct quote snippets:\n    - “**NCT06600789**: An ongoing trial by Carrick Therapeutics Limited” ([fdaaa.trialstracker.net](https://fdaaa.trialstracker.net/trial/NCT06600789/))\n    - “Title  A Modular, Multi-Part, Multi-Arm, **Phase 1/2** Study to Evaluate the Safety and Tolerability of **CT7439**…” ([fdaaa.trialstracker.net](https://fdaaa.trialstracker.net/trial/NCT06600789/))\n\n- **A Modular Phase 1/2 Study with CT7439 in Participants with Solid Malignancies — CareAcross**\n  - URL: `https://www.careacross.com/clinical-trials/trial/NCT06600789` ([careacross.com](https://www.careacross.com/clinical-trials/trial/NCT06600789))\n  - Direct quote snippets:\n    - “NCT ID:  **NCT06600789**” ([careacross.com](https://www.careacross.com/clinical-trials/trial/NCT06600789))\n    - “Study phase:  **Phase 1/Phase 2**” ([careacross.com](https://www.careacross.com/clinical-trials/trial/NCT06600789))\n    - “Intervention name:  **CT7439 Capsules (0.5 mg, 1mg, 3mg)**” ([careacross.com](https://www.careacross.com/clinical-trials/trial/NCT06600789))"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "medium",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 54967,
    "input_tokens_details": {
      "cached_tokens": 4352
    },
    "output_tokens": 6316,
    "output_tokens_details": {
      "reasoning_tokens": 5549
    },
    "total_tokens": 61283
  },
  "user": null,
  "metadata": {}
}